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ABSTRACT
Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of their
ability for self-renewal and differentiation into tissue-speciﬁc cells such as osteoblasts, chondro-
cytes, and adipocytes. MSCs orchestrate tissue development, maintenance and repair, and are use-
ful for musculoskeletal regenerative therapies to treat age-related orthopedic degenerative
diseases and other clinical conditions. Importantly, MSCs produce secretory factors that play criti-
cal roles in tissue repair that support both engraftment and trophic functions (autocrine and para-
crine). The development of uniform protocols for both preparation and characterization of MSCs,
including standardized functional assays for evaluation of their biological potential, are critical fac-
tors contributing to their clinical utility. Quality control and release criteria for MSCs should include
cell surface markers, differentiation potential, and other essential cell parameters. For example,
cell surface marker proﬁles (surfactome), bone-forming capacities in ectopic and orthotopic mod-
els, as well as cell size and granularity, telomere length, senescence status, trophic factor secretion
(secretome), and immunomodulation, should be thoroughly assessed to predict MSC utility for
regenerative medicine. We propose that these and other functionalities of MSCs should be charac-
terized prior to use in clinical applications as part of comprehensive and uniform guidelines and
release criteria for their clinical-grade production to achieve predictably favorable treatment out-
comes for stem cell therapy. STEM CELLS TRANSLATIONAL MEDICINE 2017;6:2173–2185
SIGNIFICANCE STATEMENT
There is a pressing need for more wide-ranging characterization metrics for mesenchymal stem
cells (MSCs) that better and more accurately predict treatment outcomes of MSC-based thera-
pies. This Review provides a detailed account of what are currently thought to be defining char-
acteristics of MSCs and further considers recent advances that may prove to be important
criteria when considering clinical applications. The relationship between in vitro characteristics
and in vivo potency and strategies to improve the efficacy of MSC therapy is also addressed.
INTRODUCTION
Mesenchymal stem cells (MSC) constitute a heter-
ogeneous subset of stromal regenerative cells
which can be harvested from several adult tissues.
Other descriptive names for MSC populations in
the literature include mesenchymal stromal cells,
mesenchymal progenitor cells, multipotent mes-
enchymal stromal cells, bone marrow stromal
cells, bone marrow-derived MSC, multipotent
stromal cells, mesenchymal precursor cells, skele-
tal stem cells, as well as medicinal signaling cells.
They are multipotent cells capable of differentiat-
ing into various types of specialized cells including
osteoblasts, chondrocytes, and adipocytes [1].
Recent studies indicate that MSCs resemble
pericytes and emerge from the peripheral stromal
region surrounding blood vessels, thus clarifying
their broad regenerative potential in adult tissues,
although there are also other sources for MSCs
[2–4]. Their relative ease of isolation, combined
with their capacities for self-renewal [5] and mul-
tipotentiality make MSCs a promising treatment
option for a variety of clinical conditions. Yet,
administration of MSCs (either intravenously or
by direct injection in tissue) has not yielded con-
sistent clinical results, because injected cells
exhibit limited survival in host tissue. The fact that
clinical improvement may be seen even despite
the apparent short survival times of MSCs has led
to alternative ideas about trophic effects [6].
Several wide-ranging investigations have attempted
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to address this issue of unpredictable outcomes by seeking to estab-
lish standard practices for the isolation, characterization, and main-
tenance of cells in culture. In this Review, we discuss human adult
bone marrow-derived MSCs, their various characterization methods,
including an assessment of trophic factors secreted by isolated and
culture-expanded cells. Our group has recently proposed bench-
marks for MSC functionality that require an improvement in MSC
selection criteria [7].This Review considers several functional aspects
of MSCs (Fig. 1) as they pertain to potency, and of the need to adopt
multiple-parameter analyses for useful stem cell selection.
Identification and Tissue Sources of MSCs
The ﬁrst identiﬁed multipotent stromal precursor cell populations
from the bone marrow were described as nonphagocytic,
ﬁbroblast-like in appearance and able to form adherent colonies
that were henceforth termed “colony-forming units-ﬁbroblastic”
(CFU-F) for this population [8, 9]. Other studies revealed that
bone marrow-derived MSCs represent precursor cells for mesen-
chymal tissues. Some investigations have reported conversion of
multipotent stem cells into cells from another lineage through a
process termed trans-differentiation, although there are varying
opinions on this phenomenon [10–14].While epigenetic transcrip-
tional mechanisms control neuronal versus mesenchymal cell
fates [15], MSCs can be induced experimentally to express neural
markers [16].
Although MSCs were initially identiﬁed in bone marrow, MSC-
like populations have since been harvested from autologous and
allogeneic sources, including adipose tissue [17], peripheral blood
[18, 19], lung [20], marrow spaces of long bone [21], synovial ﬂu-
ids [22], periodontal ligament [23], and muscle [24]. In addition,
MSCs are also obtained from placenta [25, 26], umbilical cord
[27], and cord blood [28, 29] as well as dental pulp [30, 31]. Inves-
tigations into the lineage of these cells strongly suggest that pro-
genitor cells of cultured MSCs arise from around the blood vessels
(capillaries, arteries and veins) in vivo, and are thus of perivascular
origin [3, 31, 32]. Notably, MSCs obtained from various sources
differ in their biological characteristics [33–36]. A recent compre-
hensive report on the proteome and transcriptome proﬁles of
MSCs revealed source speciﬁc markers [37]. In addition, differen-
ces that exist in CFU-F efﬁciency, surfactome proﬁles, multi-
lineage differentiation as well as paracrine functions [35, 36,
38–41] may determine their different clinical applications.
Recent reports have indicated that MSCs from allogeneic sour-
ces are more commonly used in trials than autologous MSCs [42,
43], even though both sources of cells have demonstrated
comparable clinical effects [42, 44–46]. Generally referred to as
“universal donor cells” [44, 47], owing to their immune tolerance
property, these cells possess several clinical advantages [48].
Nevertheless, as with any cell-based therapy, it is of utmost impor-
tance to fully evaluate the safety and efﬁcacy of allogeneic strat-
egies before clinical use [49, 50]. MSCs from bone marrow are the
most commonly investigated candidates that are providing most
of the cells being used to create functional clinical therapies. In
this Review, the isolation and functional characteristics described
pertain to human bone marrow-derived MSCs.
Isolation of MSCs
MSCs are obtained after bone marrow aspiration and then iso-
lated by sieving for plastic adherence in vitro. They readily form
colonies capable of clonal expansion and differentiation. Other
isolation methods with different degrees of sophistication have
been investigated, including density gradient cell separation [51],
as well as ﬂuorescence- or magnetic-activated cell sorting [52, 53].
The latter two ﬂow cytometric methods rely on expression of cell
surface markers displaying relatively high speciﬁcity for MSCs.
Clearly, standard isolation procedures and generic molecular char-
acterization of MSCs are vital for any consistent cell isolations [54,
55]. The key characteristics that have hitherto deﬁned MSCs have
been based on their capacity for colony formation, potential for
self-renewal, expression of surface markers, and subsequent
capacity for multilineage differentiation [56].
MULTIFACETED CHARACTERIZATION OF MSCS
Colony Formation
In vitro, plastic-adherent clonogenic cells, denoted as CFU-Fs, can
be obtained from bone marrow and give rise to colonies during
their initial growth [31, 57]. CFU-Fs are thought to be mostly com-
posed of primary bone marrow-derived MSCs that upon further
proliferative expansion in culture, constitute mesenchymal stem/
stromal cells. Colonies of MSCs display heterogeneous morpholog-
ical characteristics ranging from ﬁbroblastoid to spindle-shaped or
from large-ﬂattened to small-round cells. Passaged cells are usu-
ally seeded at 100 to 150 cells per 10-cm dish and allowed to
adhere and form colonies over a period of 14 days that are visual-
ized by staining with crystal violet or toluidine blue [58]. Evalua-
tion of the CFU-F potential is usually being done by seeding bone
marrow cells at densities of 0.5–3 million in 50–75 cm2 culture
vessels [7]. Bone marrow mononuclear cells are typically seeded
at 50,000–200,000 cells per cm2 to yield colonies of MSCs.
Although this approach provides a relatively crude estimate of
MSC titers in bone marrow cells [59], CFU-F efﬁciency remains a
routinely used and accepted standard to identify and characterize
MSCs [56].
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Figure 1. Proﬁling of MSCs. The diagram depicts the key parameters
for the characterization of adult stem cells from different sources.
Three of these parameters are linked to cell growth, survival, quies-
cence and/or senescence (i.e., viability and growth, CFU-Fs, telomere
length), two are associated with cell identity (i.e., multilineage differ-
entiation and surface marker expression), and the remaining two
refer to the ability of MSCs to communicate with their microenviron-
ment (i.e., immunomodulation and paracrine effects of trophic fac-
tors). Immunomodulation is important for regulating macrophage
function during tissue repair (e.g., M1 to M2 macrophage transition)
and for anticipating graft rejection (e.g., mixed lymphocyte reaction).
Collectively, these parameters should be considered for the develop-
ment of release criteria that validate the quality of GMP-grade MSCs
for stem cell therapy. Abbreviations: MSCs, mesenchymal stem cells;
CFU-Fs, colony-forming units-ﬁbroblastic.
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Surface Phenotype
To acquire a more complete understanding of MSC biology and to
generate a reliable stem cell product for clinical trials and routine
patient care in the future, it is necessary to isolate homogenous
population of MSCs. The principal approach for improving homo-
geneity of MSC populations uses antibodies that target speciﬁc
cell surface markers. This homogeneity is a relative term, because
MSC populations have natural variation in the expression of cell
surface markers around a common mean. The identiﬁcation of
MSCs in vivo is far from straightforward, owing to extremely low
frequencies in tissues [59, 60]. Furthermore, isolation methods
are impeded because MSCs are dynamic and exhibit phenotypic
variation over time (“plasticity”). Also, there is only a limited num-
ber of useful MSC markers, but none of these is deﬁnitively spe-
ciﬁc for MSCs in a strict sense (i.e., absolutely required and
sufﬁcient to establish MSC identity). Nevertheless, it is well estab-
lished that cultured colonies of MSCs express CD105, CD73, and
CD90, but do not express CD45, CD34, CD14 or CD11b, CD19, and
HLA-DR [56]. Some labeling strategies have also been used to suc-
cessfully isolate MSCs enriched for markers such as STRO-1 [52,
61–64], CD146 [5], SSEA-4 [65], CD271 (NGFR) [66–68], and MSC
antigen 1 (MSCA-1) [69, 70], although there is no absolute agree-
ment yet on the markers that could prospectively assist in the iso-
lation of MSCs from either fresh bone marrow or other tissues.
Initial studies by Pittenger and coworkers have identiﬁed markers
such as SH2 and SH3, which correspond to CD105 and CD73,
respectively. These markers, together with CD90, have been con-
sidered by the International Society for Cellular Therapy (ICST) as
the primary markers expressed on greater than 95% of MSCs in a
given culture. However, it should be noted that the expression of
CD105, CD90, and CD73 may not be absolutely speciﬁc to undif-
ferentiated multipotent MSCs, as some of these markers are
also expressed by vascular populations [71, 72], smooth muscle
cells [73], and mature stromal cells such as ﬁbroblasts [71, 74].
Consequently, there is a critical need to develop highly sensitive
cell sorting and immunohistochemical assays and reagents to
distinguish immature/undifferentiated MSCs from committed
stromal cell populations.
Currently not included in the ISCT panel is STRO-1, a
particularly important marker, with relatively high speciﬁcity for
early-passage bone marrow-derived MSCs. STRO-1 facilitates the
identiﬁcation, isolation, and functional characterization of
clonogenic stromal cell progenitors [52, 61–63, 75]. The absolute
selectivity of STRO-1 for na€ıve MSCs is yet to be resolved and the
presence of STRO-1 antigen on MSCs is progressively downregu-
lated following culture expansion. Notwithstanding these limita-
tions, the putative STRO-1 antigen remains very useful because
STRO-1 positive cells have favorable stem cell properties for trans-
lational applications [76].
Other strategies using cell-sorting have exploited the expres-
sion of CD49a (integrin a1; ITGA1) [39], PDGFR-a/b (platelet-
derived growth factor receptors PDGFA and PDGFB), EGF receptor
(EGFR), insulin-like growth factor receptor (IGFR), and STRO-3 [52,
77] to enable isolation of MSC populations enriched for multi-
lineage differentiation potential (see Table 1). Andersen and col-
leagues have isolated antibodies against Collagen VI (COL6A1),
CD44 and HLA-DR, and that have proven useful for identifying
subpopulations in MSC cultures [79]. CD146 (melanoma cell adhe-
sion molecule, MCAM) has attracted major interest following
reports on its expression being linked to pericytes [3, 5]. It has
also been shown that expression of CD146 on MSCs expressing
CD271 (nerve growth factor receptor, NGFR) is associated with
their in situ localization [80, 81]. However, it was also shown, par-
ticularly for CD146, that its expression is variable during in vitro
culture and its cell surface presence ﬂuctuates depending on the
type of culture media [4]. Bone marrow-derived CFU-Fs express
surface markers such as STRO-1, CD271 [68], CD49a [39, 82],
stage-speciﬁc embryonic antigen-4 (SSEA-4) [65], and CD146 [83].
CD2711 cells display multipotentiality and is considered a suita-
ble marker of bone marrow-derived MSCs [84]. Other reports
have also detailed the use of D7-FIB (a ﬁbroblast or epithelial sur-
face antigen) [85] and CD56 (neural cell adhesion molecule,
NCAM) [86] for multipotent MSC isolation. Nestin, a neural stem
cell marker, has characterized as a selective marker for bone
marrow-derived MSCs [87, 88]. On a parallel note, the use of
mouse models to study MSC biology has yielded novel informa-
tion, highlighting the similarities in the expression of some of the
surface markers, including CD140a [89, 90] and CD295 (leptin
receptor) [91], between mouse and human MSCs [92]. However,
species-speciﬁc heterogeneity in phenotype and in vivo residence
of MSCs must be taken into account when extrapolating information
derived from other species.
Lastly, it is important to understand that the innate levels of
expression of a set of surface markers are not a guarantee of MSC
homogeneity. Since labs around the world use different sets of
antigens for characterization, comparisons reveal that there is no
consistency in the use of cell surface antigens for the isolation of
MSCs and there is no marker that uniquely identiﬁes MSCs that
could be used reliably for their isolation. In our previous study
comparing in vitro and in vivo functions of bone marrow-derived
MSCs from multiple donors, we showed that STRO-1 and PDGFRa
(CD140a) were able to identify MSCs that were more potent at
forming bone in vivo [7]. We showed that MSCs with high-growth
capacity had higher levels of expression of these markers and pro-
moted increased bone-formation compared with low-growth
capacity cells, thus highlighting the possible utility of STRO-1 and
PDGFRa markers to aid in selection of efﬁcacious MSCs for bone
regenerative applications. Also, it is important to note that MSCs
from different tissue origins have different surface marker expres-
sion [93, 94]. Consequently, investigators are now performing
characterization to determine the genomic and proteomic proﬁles
of MSCs to establish mechanisms that mediate self-renewal and
maintenance of homogenous cell populations. In keeping with the
trophic functions of MSCs (see below), their secretory and
exosomal proﬁles may reveal unique biomarkers that reﬂect their
biological properties and could potentially aid in their selection.
Multi-Lineage Differentiation
While surface markers are easily assessable, a proper deﬁnition of
what constitutes an MSC can be completed by their ability to dif-
ferentiate into classic mesodermal lineages of bone, fat, and carti-
lage. When late passage cultures are left in maintenance media
for longer periods (weeks) and cells become conﬂuent, at least a
subset is capable of spontaneously mineralizing, indicating that
bone-marrow MSCs are predisposed to differentiation into the
bone lineage [95]. This property is not exclusive of bone marrow
MSCs and is also exhibited by human umbilical cord perivascular
cells [96]. Factors such as ascorbic acid and dexamethasone, at
deﬁned concentrations, are able to direct the MSCs toward osteo-
genic differentiation. Similarly, BMPs, WNTs, FGFs and other
heparan sulfate-sensitive morphogens, and growth factors are
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Table 1. Surface antigen expression on human bone marrow-derived mesenchymal stem cells (MSCs)
CD (cluster of differentiation) Gene Symbol Protein description MSC speciﬁcity
CD11a ITGAL Integrin alpha L chain –
CD11b ITGAM Integrin alpha M chain –
CD13 ANPEP Aminopeptidase N –
CD14 CD14 Myeloid cell-speciﬁc leucine-rich glycoprotein –
CD19 CD19 B-lymphocyte surface antigen B4 –
CD29 ITGB1 Integrin b1 chain 1
CD31 PECAM1 Platelet endothelial cell adhesion molecule 1
CD34 CD34 Hematopoietic progenitor cell antigen CD34,
transmembrane phosphoglycoprotein
1/–
CD36# CD36 Collagen Type I Receptor, Thrombospondin Receptor 1/–
CD44# CD44 Hyaluronan receptor 1
CD45 PTPRC Lymphocyte common antigen; protein tyrosine
phosphatase, receptor type, C
–
CD49a ITGA1 Integrin subunit alpha 1 chain 1
CD49b ITGA2 Integrin subunit alpha 2 chain 1
CD49c ITGA3 Integrin subunit alpha 3 chain 1
CD49d ITGA4 Integrin subunit alpha 4 chain 1
CD49e ITGA5 Integrin subunit alpha 5 chain 1
CD51 ITGAV Integrin subunit alpha V chain 1
CD54 ICAM1 Intracellular adhesion molecule 1
CD58 CD58 Lymphocyte function-associated antigen 1
CD61 ITGB3 Integrin b3 chain 1
CD71 TFRC Transferrin receptor 1
CD73* NT5E Ecto-5’-nucleotidase 1
CD90* THY1 Thy-1 1
CD102 ICAM2 Intracellular adhesion molecule 1
CD104 ITGB4 Integrin b4 chain 1
CD105* ENG Endoglin, TGFb R III 1
CD106 VCAM1 Vascular cell adhesion molecule 1
CD120a TNFRSF1A Tumor necrosis factor receptor 1A, TNF IR 1
CD120b TNFRSF1B Tumor necrosis factor receptor type II, TNF IIR 1
CD121a IL1R1 Interleukin-1 receptor 1
CD124 IL4R Interleukin-4 receptor 1
CD133 PROM1 Prominin-1 transmembrane glycoprotein –
CD140a PDGFRA Platelet-derived growth factor receptor alpha 1
CD140b PDGFRB Platelet-derived growth factor receptor beta 1
CD146 MCAM Melanoma cell adhesion molecule 1
CD166 ALCAM Activated leukocyte cell adhesion molecule 1
CD200 CD200 OX-2 membrane glycoprotein 1
CD221 IGF1R Insulin-like growth factor 1 receptor, IGF-R 1
CD271 NGFR Nerve growth factor receptor, NGF-R 1
SSEA-4 SSEA4 Stage speciﬁc embryonic antigen-4 1
STRO-1 N.A. Stromal antigen 1 1
W8-B2/MSCA-1 N.A. MSC antigen 1 1
The signs (1) or (–) indicate the presence or absence of markers respectively. * refers to antigens that have been proposed by the International
Society for Cellular Therapy (ISCT) to deﬁne human MSCs [56]; # refers to markers speciﬁcally retained by adipose stem cells, according to the
recently revised ISCT and International Federation for Adipose Therapeutics and Science joint statement [78]. Abbreviation: N.A., not available.
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able to stimulate osteogenic differentiation [97–102]. To stimulate
adipogenesis, dexamethasone, indomethacin, insulin, and isobu-
tylmethylxanthine are usually added to the cultures [103].
Ascorbate, insulin, transferrin, selenic acid, and TGF-b are well-
established inducers of chondrogenesis [104–106]. It is broadly
appreciated that differentiation protocols followed by laboratories
around the world are not necessarily the same. Factors such as
antibiotics and growth supplements such as serum and platelet
lysate can inﬂuence the phenotypic properties of MSCs and their
multi-lineage potential [107–109].
We note that when cultured under deﬁned conditions with
speciﬁc inducing factors, MSCs can be directed to differentiate
into neural, myocyte, and epithelial cells, thereby demonstrating
their endodermic and neuroectodermic differentiation potential
[14, 95, 110, 111]. It is not clear whether this process represents
culture-induced aberrant trans-differentiation or perhaps reﬂects
the inherent natural ability of adult stromal cells to reprogram
under speciﬁc conditions. Forced trans-differentiation in culture
may perhaps be analogous to established developmental events
(e.g., neural crest formation, epithelial-to-mesenchymal, and
endothelial-to-mesenchymal transitions). In several studies using
in vivo transdifferentiation models, MSCs have been reported to
engraft and differentiate resulting in functional improvement of
endogenous tissues [112–117], as well as integrate via cell fusion
mechanisms [118–120].
Differences exist in MSC differentiation properties. Culture-
expanded colonies display progressively limited differentiation
potential. Reports from various groups have suggested that only a
fraction of the total number of clones can differentiate into all the
three lineages. The majority of the clones appear to be bi-potent
and only able to commit to osteogenic and chondrogenic lineages.
Clones that showed increased adipogenic potential had decreased
chondrogenic potential, and vice versa. From our previous work,
we observed a bimodal differentiation pattern in MSCs that alter-
nate between osteogenesis and adipogenesis [7]. Furthermore,
monopotent MSCs have also been reported [121–123]. Thus, tri-,
bi-, and mono-potent colonies have been identiﬁed.
The reasons for heterogeneity in differentiation potential are
not fully understood, but most likely reﬂect epigenetic adapta-
tions that predispose cells to different cell fates depending on the
source tissue. The latter concept remains conjecture at present,
but is a logical implication from current concepts of the physiolog-
ical micro-environment of stromal cells. For example, stromal cells
surrounding blood vessels in fat tissue or the bone marrow cavity
are exposed to different growth factors, morphogens, cytokines
and chemokines. Ultimately, such extracellular signals are sensed
by cell surface receptors and transduced to the nucleus to medi-
ate epigenetic chromatin changes. The latter changes are more
likely to ensure that stromal cells in fat tissue differentiate into
pre-adipocytes, while analogous stromal cells in bone marrow
may more easily convert into skeletal progenitor cells.
Considering the heterogeneity in lineage-predisposition of differ-
ent MSC preparations, characterization of the lineage-differentiation
potential is important, albeit that it is not prudent to base MSC
selection solely on this biological property. Differentiation properties
of MSCs are important for tissue maintenance and repair, as well as
engineering strategies, and cell-based therapies that require engraft-
ment and differentiation into host tissues. However, the clinical
potential of the trophic functions of MSCs is recently gaining signiﬁ-
cant traction as the basis for new stem cell therapies.
Trophic Functions of MSCs
The trophic function of MSCs refers to their functional capacity to
generate a reparative milieu through cell-to-cell contact concomi-
tant with paracrine secretion of a broad array of bioactive macro-
molecules that promote immunomodulation of inﬂammatory
cells that participate in tissue repair (e.g., T cells, macrophages,
and mast cells) and differentiation of endogenous progenitor cells
(e.g., osteo- and chondroprogenitors). The current catalogue of
trophic factors includes growth factors, morphogens, chemokines,
cytokines, extracellular vesicles ([EVs] e.g., exosomes), and glycos-
aminoglycans (GAGs) [6, 124–128] (Fig. 2). The immunomodula-
tory properties of MSCs support suppression of local immune
responses and ﬁbrotic tissue formation, while modulating angio-
genesis, apoptosis, and cell proliferation. These properties collec-
tively generate a microenvironment that enables injured tissues
to mount a self-regulated regenerative response [129, 130].
Historically, MSCs originally attracted attention because of
their “stemness” and potential use as therapeutic agents through
engraftment to replace cells in damaged tissues. However, in
many experimental settings, transplanted cells restore tissue func-
tions with no detectable engraftment within host tissue or differ-
entiation [131–133]. Reports on the trophic functions of MSCs
date back to studies by Dexter and colleagues, that showed the
ability of MSCs to support HSCs [134], to be able to suppress the
local immune system by secretion of cytokines [131, 135, 136], to
Routine tissue 
maintenance
Trophic and 
paracrine activities
Response to injury
TISSUES SECRETED FACTORS
Fat
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Figure 2. Dual functions of MSCs in tissue regeneration and repair. MSCs play a central role during regeneration and repair of musculoskel-
etal tissues (i.e., bone, cartilage, ligament, tendon, muscle and synovium). In addition, MSCs provide a microenvironment for hematopoietic
stem cells, including cells of the myeloid and lymphoid lineages. Effects of MSCs on their microenvironment are mediated by secretion of
trophic factors that have both autocrine and paracrine functions. Abbreviation: MSCs, mesenchymal stem cells.
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aid in regeneration of the meniscus [137], to promote neurotro-
phic and functional recovery after stroke [138], and promote car-
diac repair [139]. The mechanisms governing these functions
imply that MSCs facilitate normal tissue healing by cell-to-cell
contact and/or secretion of bioactive factors.
Several published ﬁndings reinforce the proposition that persis-
tent engraftment of the cells at a skeletal defect site is not manda-
tory for tissue healing or repair. Horwitz and colleagues showed
that OI (osteogenesis imperfecta) in babies was improved with
transplantation of allogenic bone marrow cells, and resulted in
increased bone mineral density and reduced bone fractures, even
though less than 2% of the donor MSCs were found to be engrafted
[140]. Other studies have shown that few implanted MSCs survive
6 weeks post-implantation in a rat ectopic model [141] and 3 to 7
weeks in an orthotopic femoral defect model [100]. The observed
bone regeneration is attributable to a burst of active trophic factors
secreted by the implantedMSCs. Similarly, MSC transplants in other
disease models have resulted in improved cardiac function, neuro-
genesis, pancreatic islet survival and functionality, as well as modu-
lation of the immune system in graft-versus-host-disease [142].
These ﬁndings are generally consistent with the now prevalent idea
that MSCs do not promote tissue repair only through engraftment,
but also by delivery of bioactive factors.
Given the therapeutic potential of EVs secreted by MSCs
[143–146], it would be useful to include characterization of EVs
while assessing MSC potency. EVs have been shown to possess
anti-inﬂammatory properties [147], rescue radiation damage to
bone marrow MSCs [148], as well as mitigate airway hyper-
reactivity and lung inﬂammation in preclinical disease models
[144]. Assaying for their reported immunomodulatory, cytoprotec-
tive, and regenerative properties may be important for advancing
MSC-based EV-mediated therapies [147, 149, 150].
Despite the fact that MSCs isolated from separate donors
show no major differences in their in vitro differentiation potential
or in their surface markers expression [151], differences in their
secretion proﬁle may be the key to the observed variability in their
in vivo healing capacity. The in vitro secretome of MSCs has been
well documented and several secretory molecules relevant to
MSC potency have been investigated [7]. Although recombinant
bioactive factors are essential for the future of regenerative medi-
cine, the use of most of them remains experimental, mainly due
to difﬁculties in optimizing the clinical dose of the factors based
on in vitro results and preclinical models. Understanding the
secretory activity of MSCs, in conjunction with their in vivo behav-
ior and paracrine effects, is thus of paramount importance for the
exploitation of their clinical potential.
Immunomodulatory Properties of MSCs
The mechanisms underlying immunoregulation by MSCs are not
fully understood, but involve cell-to-cell contact and secretory
mechanisms. Typical in vitro modulatory functions of MSCs are inhi-
bition of T cell [152] and B cell proliferation, as well as dendritic cell
differentiation [153]. MSCs also regulate immune responses by
upregulating the numbers of regulatory T cells (Tregs) which actively
suppress effector T cell functions [154]. MSC-immune cell contact
involves adhesion molecules [155]. In addition, factors including IL-
10, indoleamine 2, 3-dioxygenase (IDO), VEGF, CCL-5 or RANTES,
prostaglandin E2, and nitric oxide (NO) are secreted byMSCs (either
constitutively or by interaction with target cells). Interleukin-6 (IL-6),
TGFb1, hepatocyte growth factor, CCL-1 or MCP-1 (monocyte che-
moattractant protein), and leukemia inhibitory factor (LIF) are other
notable immunoregulatory factors secreted by MSCs [156, 157].
MSC-to-T cell contact induces IL-10 secretion, which attenuates T
cell proliferation, and stimulates HLA-G5 secretion which in turn
inhibits activated Tcells and NK-cell cytotoxicity [158] (Fig. 3).
In vivo, systemic administration of MSCs facilitates immuno-
suppression in graft-versus-host-disease models [159], multiple
sclerosis, inﬂammatory bowel disease, diabetes [160] as well as
cardiomyopathies [161, 162]. Following successful outcomes from
animal models, clinical trials for Crohn’s disease (e.g., Mayo Clinic),
acute graft-versus-host-disease (e.g., Osiris Therapeutics), and
severe osteogenesis imperfecta by allogenic BMT (e.g., St. Jude
Children’s Research Hospital) have been conducted. Trials are
ongoing for acute myocardial infarction, aplastic anemia, osteoar-
thritis, SLE, diabetes, and other conditions [142, 163]. Because
MSC therapy appears to be promising for treating immunological
disorders, characterization of MSC immunosuppressive functions
will provide an important functional indicator for in vivo efﬁcacy
of MSCs, even though they may not be speciﬁc to multipotent
MSCs, since stromal ﬁbroblasts also exhibit immunosuppressive
functions [164, 165]. Furthermore, it is also important to note
that MSCs from different sources may differ in their mechanisms
and capacities for immunomodulation [166].
Because of their trophic and immunomodulatory functions,
MSCs are generally considered to possess greater advantages in
cell-based regenerative medicine. However, it is important to note
that MSCs can either support or suppress tumorigenesis
(reviewed in [167, 168]). In contrast to their anti-apoptotic and
anti-inﬂammatory functions, MSCs have been shown to interact
with tumor cells via paracrine signaling and possibly increase the
risk for metastasis by mediating epithelial-to-mesenchymal transi-
tion in addition to augmenting angiogenesis [169–172]. This less-
desirable effect imparted by MSC immunomodulatory activities at
tumor microenvironments warrants some caution in their use in
circumstances of pre-existing tumor conditions.
T cell
B cell
Dendritic cell
Treg
IDO
TGFβ1
PGE2
PGE2 PGE2
IL-10
TGFβ1
MSC
Figure 3. Interactions of MSC with immune cells. MSCs secrete
soluble molecules, such as nitric oxide, PGE2, IDO, IL-10 and TGFb1.
The secretion of these factors suppresses the proliferation and/or
activity of a variety of immune cells, including T cells, B cells, Natural
Killer cells, and dendritic cells, as well as activated Tregs. Abbrevia-
tions: IDO, indoleamine 2, 3-dioxygenase; IL-10, interleukin-10;
MSCs, mesenchymal stem cells; PGE2, prostaglandin; TGFb1, trans-
forming growth factor-beta 1; Tregs, regulatory T cells.
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Telomere Length Analysis
Cell preparations of MSCs have variable and limited proliferative
potential. The variability depends on differences in sources and
methods of isolation, as well as the age and health conditions of
the donors [173, 174]. For clinical use, extensive subculturing is
performed to attain the required cell numbers for therapy. As a
result, cells rapidly reach a stage of growth arrest and replicative
senescence as their telomeres progressively shorten with
repeated cell replications in vitro. Obtaining both quality and
quantity of MSCs for an efﬁcacious therapy is a major bottleneck
in translational medicine. Telomere maintenance is carried out via
telomerase reverse transcriptase (hTERT) which functions to
lengthen telomeres by adding repetitive TTAGGG sequences to
chromosome termini. Overexpression of TERT in MSCs restores
telomerase activity, preserves telomere length and increases MSC
life span. The status of telomeres is a key parameter for MSC qual-
ity that should be routinely monitored; however, reports on telo-
merase functions in MSCs are incompatible [111, 175, 176].
Differences in results could be due to different sensitivities in
measurement and the nonestablished reference levels of telomer-
ase to deﬁne cells as either telomerase-positive or negative [177].
Therefore, assaying for telomere lengths, as well as overall
telomere status in MSCs should assist in the benchmarking
process and in quality control decisions required before MSC
transplantation [7, 178].
STANDARDIZATION OF STRATEGIES FOR IMPROVING MSC
GROWTH AND REGENERATIVE EFFICACY
Uniform standards for MSC preparation are essential for funda-
mental characterization and clinical translation of MSCs. Standard
operating procedures avoid variability in cell preparation that may
arise for technical reasons. Yet, currently most laboratories use
their own optimized protocols, and cell preparations between
labs clearly vary. Therefore, it would be beneﬁcial for laboratories
to agree upon standard operating procedures and to improve
comparison of results.
The illustration provided in Figure 4 is a schematic of a BM
aspirate sample processing. The aspirate is layered over Ficoll-
Paque to obtain mononuclear cell fractions by density gradient
method, from which MSCs are isolated. Between 1 and 3 million
MNCs are seeded in 50–75 cm2 dishes or ﬂasks to obtain colonies
that provide an estimate of MSC numbers per 105 cells seeded.
Flow cytometry is performed to determine the MSC percentages
in the original sample before they are plated for isolation to get
the baseline MSC levels in a given patient/donor sample. Also,
growth capacities of cells (fast or slow growing) are assayed start-
ing at P0 by taking a fraction of the MNCs and allowing MSC colo-
nies to form and proliferate so that cumulative growth can be
plotted. Cells that have undergone three or four passages are typi-
cally evaluated for matching the ISCT criteria [56]. In addition,
other criteria such as population doubling time, amounts of
growth factor/cytokine secretions, levels of STRO-1, PDGFR-a/b,
and telomere length are some measures to assess efﬁcacy.
Strategies to clear the hurdle of achieving clinically relevant
numbers of MSCs include the use of growth media supplements
like serum, platelet lysates, growth factors, and so forth. Impor-
tantly however, the use of such supplements is currently hindered
by their cost, degradation in culture and thus their limited bioac-
tivity. It is to be noted that the transfer of retained non-human
antigens from serum may elicit an inappropriate immune
response upon transplantation [179, 180], and therefore necessi-
tates the use of human-derived components such as plasma or
Passaging: 
~70 - 80% 
confluent
BM sample storage and 
processing
Transported on ice (within 1-2h)
Cryopreserved immediately
Aspiration of BM
and Ficoll separation 
BM-mononuclear cells
seeding: 50,000 cells/cm2
Culture: 
1st media change at 
day 4; every 3 - 4 
days thereafter 
CFU-F 
1-3 million MNCs
ISCT criteria
Adherence to plastic
Surface markers
Multilineage differentiation
ISCT 
Growth capacity and PD*
Trophic factor secretion*
STRO-1 and PDGFR-α,β* 
Telomere length
Flow cytometry
HSC and MSC markers
STRO-1
Cumulative growth
Track cPD
Fast vs Slow growth
Establishing release criteria
Figure 4. Standard operating procedures for isolating mesenchymal stem cells (MSCs). The diagram shows the basic steps for isolating and
validating MSCs from bone marrow aspirates derived from either human donors or patients, including evaluation of key potency parameters
of these cells before release to the clinic. Abbreviations: BM, bone marrow; cPD, cumulative population doubling; HSC, hematopoietic stem
cells; ISCT, International Society for Cellular Therapy; MNC, mononuclear cells; PD, population doubling; PDGFR-a, platelet-derived growth
factor receptor-alpha; STRO-1, stromal antigen-1. Asterisk (*) indicates proposition of additional criteria that could potentially facilitate better
selection of MSCs.
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serum platelet lysate as a suitable alternative [181, 182]. Sustain-
ing the bioactivity of growth factors can be achieved by harnessing
their interaction with GAGs such as heparan sulfate (HS) [100]. HS
GAGs that bind to growth factors with high afﬁnity can be puriﬁed
using well-established chromatographic techniques [100, 183].
Introducing GAGs to the culture at the time of isolation, and pre-
conditioning cells in HS appears to be a promising approach to
improve MSC numbers while maintaining their characteristics. On
the contrary, heparin has been shown to alter biological proper-
ties of MSCs and is not a recommended additive [184]. HS-GAGs
could interact and protect growth factors from extracellular pro-
teases, as well as from pH and thermal changes, so enhancing
growth factor activity and downstream signaling, and ultimately
stimulating MSCs to proliferate and be useful for tissue repair and
regeneration. More recently, pre-conditioning strategies using
BMP-2 and Wnt5a has proven useful for cartilage repair [185].
ECONOMIC POTENTIAL AND MARKET IMPACT OF MSC RESEARCH
AND THERAPIES
Stem cells are central components of regenerative medicine hold-
ing huge market potential that is projected to reach $170 billion by
2020, as per recent reports by Grand View Research, Inc. published
in 2015. Several unmet medical needs drive the stem cell research
economy. The consumers of this market are usually hospitals, clini-
cal laboratories, stem cell banks, and academic institutes. Adult
stem cells dominate the market as they do not raise the ethical
controversy that surrounds embryonic stem cells, as well as due to
relatively low production labor and maintenance costs, lower risk
of tumors, and better immunocompatibility [186–189].
Human MSCs are currently administered for several clinical
conditions, including bone, heart, neurodegenerative, and immu-
nological disorders, and have reached phase I and II clinical trials
[190]. We performed a search using the keyword “mesenchymal
stem cell” in ClinicalTrials.gov in order to ﬁnd the number of stud-
ies conducted worldwide.The potential of MSCs for clinical applica-
tions is supported by the fact that the clinical trials database
currently lists nearly 650 clinical trials globally, excluding studies of
unknown status (Fig. 5A) [Source: https://ClinicalTrials.gov]. Most
of the trials in phase II are for conditions such as osteoarthritis,
neurological diseases, pulmonary disorders, spinal cord injury,
myocardial infarction, severe coronary ischemia, Crohn’s disease,
and diabetes mellitus. There is a strong correlation between global
economic burden due to health disorders and the potential for
stem cells to treat such ailments. We performed a Scopus search
using strings “hematopoietic stem cells,” “embryonic stem cells,”
“mesenchymal stem cells,” “neuronal stem cells,” “induced pluri-
potent stem cells,” and “umbilical cord stem cells” to assess the
number of research articles published between 1995 and 2015.
Clearly, research trends keep pace with market trends alongside
clinical trials (Fig. 5B), and it is anticipated that this industry will
continue to open up, with products for cardiovascular, diabetes,
and nerve repair becoming commercially available. To accelerate
this, it is important that the new 3Rs (regulation, reimbursement,
and realization of value) recently proposed by Caplan and
colleagues are taken into consideration [191]. As MSC research
continues to increase (Fig. 5B), the overall revenue for adult stem
cell products is estimated at $10.9 billion by the end of this decade
(Source: http://www.grandviewresearch.com).
In recent years, as cell preparations of MSCs become commer-
cially available, several stem cell companies have formulated their
own criteria for the selection of clinical grade cells: for example,
the enrichment for STRO-11 and STRO-31 mesenchymal precur-
sor cells by Mesoblast [64, 192], and the selection of MSCs secret-
ing TNF-a receptor Type I at a minimum of 13 pg/10 million cells
deﬁned by Osiris Therapeutics [193]. Another important develop-
ment was the identiﬁcation of a subpopulation of MSCs by Smith
and colleagues, which are characterized by their smaller size and
rapid self-renewal potency. These cells are enriched for precursor
cells that could be efﬁcacious for therapy [194]. Stempeutics
Research’s speciﬁcations for their allogeneic BMMSC product,
Stempeucel, includes parameters such as morphology (ﬁbroblastic
and spindle-shaped), cell counts of 180–220 million cells per bag,
viability of >85%, ISCT-deﬁned surface marker levels >80% along
with CD166> 80% [71] and CD133< 5% as their release criteria
for administration [195, 196]. As more strategies evolve and new
criteria are published, the selection panel is continuously being
developed. Therefore, it is essential to adopt broader characteriza-
tion schemes if we seek to better understand MSC function and
utility for commercial and clinical applications.
CONCLUSION
There is a compelling need to broaden the characterization land-
scape by identifying novel stable markers and reﬁning selection
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Figure 5. Mesenchymal stem cells (MSCs) in clinical trials and stem cell market forecast. (A): MSC-based clinical trials were charted by
region based on search results sourced from https://ClinicalTrials.gov (retrieved July 1, 2017). (B): Scopus search results show the number of
stem cell research articles published between 1995 and 2015, indicating the rising number of published studies on MSCs (retrieved July 1,
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criteria for establishing optimal classes of MSCs. Yet, current deﬁ-
nitions of MSCs based on surface markers and/or differentiation
parameters have so far been incomplete. Differences in the cellu-
lar phenotypes of MSCs can be attributed to the methods by
whichMSCs are isolated and expanded, ways of handling the cells,
particularly seeding densities and media supplements, as well as
other components of the culture conditions. The technical discrep-
ancies in methods for deﬁning MSC characteristics prevents gen-
eral interpretations of results from stem cell laboratories or any
beneﬁcial effects of stem cell therapies observed in clinical trials
with a range of stem cell preparations. Therefore, it is essential to
obtain uniformity of methods for isolating and characterizing
MSCs. To address ambiguities related to MSC identiﬁcation and
function, the ISCT criteria aimed to standardize isolation methods
by serving as the basis for characterization of these cells, and to
enable comparison of investigations among laboratories. This initi-
ative is a key step in the right direction, but many more steps
remain to be taken. Deﬁnition of novel biomarkers using genomic,
epigenomic, transcriptomic, proteomic and metabolomic
approaches, beyond the classical techniques that measure colony-
forming ability, CD marker expression, telomere length and cellular
morphology (among a myriad of other tests) may collectively pro-
vide for a new generation of highly sophisticated standardized
tests as necessary quality control parameters for characterization
of MSC preparations in clinical practice.
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